Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01415102 | A First In Human Study In Healthy People To Evaluate Safety, Toleration And Time Course Of Plasma Concentration Of Single Inhaled Doses Of PF-05212372. | PHASE1 | COMPLETED | 24 | — | — | Sep 1, 2010 | Dec 1, 2010 | Aug 15, 2011 | 1 | Belgium |
| Arm | Type | Description |
|---|---|---|
| Cohort 1 | EXPERIMENTAL | Subjects will be assigned to receive either PF-05212372 or placebo in each period |
| Cohort 2 | EXPERIMENTAL | Subjects will be assigned to receive either PF-05212372 or placebo in each period |
| Name | Type | Description |
|---|---|---|
| PF-05212372 | DRUG | Inhaled. Dose Level 1: 50 ug |
| Placebo | DRUG | Inhaled |
Inclusion Criteria: Healthy subjects. (Healthy is defined as no clinically relevant abnormalities identified by a detailed medical history, full physical examination, including blood pressure and pulse rate measurement, 12-lead ECG and clinical laboratory tests). Exclusion Criteria: * Evidence or...